SIGASIGAHealthcare · Drug Manufacturers - Specialty & Generic

SIGA Stock Forecast: SIGA Technologies, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$2.80
+2.56% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$196.2M
Ticker Nerd rank
51/ 100
Median analyst target
—
Analysts covering
0
Revenue$41.0M−49.5% y/y
Operating income$13.9M
Net income$12.5M
Free cash flow$15.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.8%
1M
−11.7%
YTD
−49.0%
1Y
−47.8%
From 52W high
−55.1%
From 52W low
+2.6%
$2.73
$6.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SIGA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SIGA Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
51/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Value
89
Quality
76
Issuance
74
Size
65
Accruals
46
Revisions
25
Growth
17
Momentum
14

Volatility (97): The share price has been relatively steady.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SIGA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SIGA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26SIGA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Nov 2012WedbushMaintainsOutperform$11 → $7.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SIGA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SIGA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, SIGA Technologies, Inc. returned −47.8% against +12.2% for the S&P 500, dividends included.

SIGA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26SIGAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SIGA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−60.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

SIGA Technologies, Inc. (SIGA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
281.5×

Cheaper than 2% of US stocks

Price / sales
3.9×

Cheaper than 30% of US stocks

Price / book
1.2×

Cheaper than 63% of US stocks

EV / EBITDA
−11.7×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−49.7%

Higher than 6% of US stocks

Earnings growth (YoY)
−49.5%

Higher than 11% of US stocks

Gross margin
57.2%

Higher than 70% of US stocks

Operating margin
−14.2%

Higher than 23% of US stocks

Net margin
1.3%

Higher than 50% of US stocks

Returns & dividend
Return on equity
0.4%

Higher than 44% of US stocks

Return on assets
−2.3%

Higher than 36% of US stocks

Dividend yield
85.1%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SIGA Technologies, Inc. (SIGA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SIGA Technologies, Inc. has a market value of $196.2M and an enterprise value of $80.1M.

  • Revenue in the twelve months to 30 June 2026: $53.7M. The latest quarter shrank 49.7% year on year.

  • Net income over the same four quarters: −$2.8M, a −5.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$20.5M, after $330K of capital spending.

  • SIGA Technologies, Inc. spent $43.6M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 71.8M.

  • Trailing P/E: 281.5×; forward P/E: 2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 85.11%, paying out 0% of earnings.

  • SIGA Technologies, Inc. employs 49 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

SIGA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SIGASIGA Technologies, Inc.$196.2M51
ADCTADC Therapeutics SA$189.9M86
ANIKAnika Therapeutics, Inc.$172.2M98
BIOABioAge Labs, Inc.$226.3M16
LFCRLifecore Biomedical, Inc.$242.2M2
EBSEmergent BioSolutions, Inc.$290.4M80
TLRYTilray Brands, Inc.$347.3M16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SIGA Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SIGA news & analysis

SIGA Technologies, Inc. (SIGA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 10 Nov 2026neutral

Seeking Alpha published a transcript of SIGA Technologies, Inc.’s Q3 2026 earnings call. The provided text contains no details from the call.

Why it matters — SIGA watchers can note the transcript’s availability, but the excerpt does not provide information about the company’s results or outlook.

What Siga Technologies (SIGA) Said on Its Q3 Earnings Call

MarketBeat · 10 Nov 2026neutral

SIGA said it continues to expect a new U.S. government procurement contract for its smallpox treatment TPOXX, but the timing remains uncertain following a slower-than-expected contracting process.

Why it matters — The update concerns the expected procurement contract for TPOXX and uncertainty about when it may be finalized.

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

GlobeNewsWire · 9 Nov 2026neutral

SIGA Technologies announced that Executive Vice President and Chief Scientific Officer Dennis Hruby, Ph.D., will retire effective Nov. 9, 2026, after more than 30 years with the company.

Why it matters — SIGA watchers may note the departure of a long-serving senior scientific executive.

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026

GlobeNewsWire · 9 Nov 2026positive

SIGA reported financial results for the three and nine months ended September 30, 2026. The company also disclosed a $15 million Canadian Department of National Defence procurement contract for oral TPOXX awarded in October.

Why it matters — The results and Canadian contract provide updates on SIGA’s performance and international TPOXX business as it continues discussions with the U.S. Government about a new procurement contract.

SIGA to Host Business Update Call on November 9, 2026, Following Release of Third-Quarter 2026 Financial Results

GlobeNewsWire · 29 Oct 2026neutral

SIGA Technologies announced that management will host a business update webcast and conference call at 4:30 p.m. ET on November 9, 2026, following the release of its third-quarter 2026 financial results. CEO Diem Nguyen and CFO Daniel Luckshire will participate.

Why it matters — SIGA watchers may follow the call for management’s business update and discussion of the quarterly results.

FAQ

Frequently asked questions about SIGA stock

How does Ticker Nerd's model rank SIGA?

As at 17 Nov 2026, SIGA Technologies, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

What is the SIGA stock forecast for 2030?

No analyst covering SIGA Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SIGA are extrapolating price history, which says nothing about the business.

How has SIGA stock performed over the past year?

SIGA Technologies, Inc. returned -47.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SIGA Technologies, Inc. do?

SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on health security and infectious disease countermeasures.

What is the latest news on SIGA?

The most recent item we track (Seeking Alpha, 10 Nov 2026): "SIGA Technologies, Inc. (SIGA) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of SIGA Technologies, Inc.’s Q3 2026 earnings call. The provided text contains no details from the call.

Company

About SIGA Technologies, Inc.

SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on health security and infectious disease countermeasures. SIGA Technologies Inc. develops and commercializes antiviral medicines designed to address serious threats from orthopoxviruses and other emerging infectious diseases. Its lead product, TPOXX, is an oral antiviral treatment for smallpox, and the company also supplies an intravenous formulation for government use in public health preparedness settings. SIGA Technologies Inc. serves government customers and international markets through direct sales and distribution channels, making it a specialized participant in the biodefense and medical countermeasures segment of the pharmaceutical industry. Based in New York, SIGA Technologies Inc. concentrates on products that support outbreak response, national stockpiling, and treatment access for high-consequence viral diseases.

CEO Dr. Diem Nguyen M.B.A., Ph.D. · 49 employees · United States · https://www.siga.com